

2nd Annual Southern California Genitourinary Cancer Research Forum

## Key Updates from 2024 in Kidney Cancer

Alex Chehrazi-Raffle, MD

Assistant Professor, Division of Medical Oncology & Experimental Therapeutics

City of Hope Comprehensive Cancer Center



• Consultant for Eisai, Exelixis, and Pfizer.

This presentation and/or comments will be free of any bias toward or promotion of the above referenced companies or their product(s) and/or other business interests.

*This presentation and/or comments will provide a balanced, non-promotional, and evidence-based approach to all diagnostic, therapeutic and/or research related content.* 

This presentation has been peer-reviewed and no conflicts were noted.

## Cultural Linguistic Competency (CLC) & Implicit Bias (IB)

### **STATE LAW:**

The California legislature has passed <u>Assembly Bill (AB) 1195</u>, which states that as of July 1, 2006, all Category 1 CME activities that relate to patient care must include a cultural diversity/linguistics component. It has also passed <u>AB 241</u>, which states that as of January 1, 2022, all continuing education courses for a physician and surgeon **must** contain curriculum that includes specified instruction in the understanding of implicit bias in medical treatment.

The cultural and linguistic competency (CLC) and implicit bias (IB) definitions reiterate how patients' diverse backgrounds may impact their access to care.

### **EXEMPTION:**

Business and Professions Code 2190.1 exempts activities which are dedicated solely to research or other issues that do not contain a direct patient care component.

This presentation is dedicated solely to research or other issues that do not contain a direct patient care component.

## RCC Highlights from 2024

### ASCO GU

 Overall survival results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab versus placebo for the treatment of clear cell renal cell carcinoma

### <u>ASCO</u>

 Circulating kidney injury molecule-1 (KIM-1) biomarker analysis in IMmotion010: A randomized phase 3 study of adjuvant atezolizumab vs placebo in patients with renal cell carcinoma at increased risk of recurrence after resection

### <u>ESMO</u>


 Tivozanib Plus Nivolumab vs Tivozanib Monotherapy in Patients with Metastatic Renal Cell Carcinoma Following an Immune Checkpoint Inhibitor: Results of the Phase III TiNivo-2 Study

## RCC Highlights from 2024 – ASCO GU

<u>Overall survival results from the phase 3 KEYNOTE-</u> <u>564 study of adjuvant pembrolizumab versus</u> <u>placebo for the treatment of clear cell renal cell</u> <u>carcinoma (ccRCC)</u>

### IMMotion010

### CheckMate 914



2024 ASCO ANNUAL MEETING #ASCO24 PRESENTED BY: Laurence Albiges, MD, PhD | IMmotion010 biomarker (#4506) Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org. ASCO<sup>®</sup> AMERICAN SOCIETY OF CLINICAL ONCOLOGY KNOWLEDGE CONQUERS CANCER

### KEYNOTE-564 Study (NCT03142334)

### Key Eligibility Criteria

- Histologically confirmed clear cell RCC with no prior systemic therapy
- Surgery ≤12 weeks prior to randomization
- Postnephrectomy intermediate-high risk of recurrence (M0):
  - pT2, grade 4 or sarcomatoid, N0
  - pT3, any grade, N0
- Postnephrectomy high risk of recurrence (M0):
  - pT4, any grade, N0
  - Any pT, any grade, N+
- Postnephrectomy + complete resection of metastasis (M1 NED)
- ECOG PS 0 or 1


Stratification Factors

M stage (M0 vs. M1 NED)

• M0 group further stratified:

• US vs. non-US

• ECOG PS 0 vs. 1



### Primary Endpoint

· Disease-free survival by investigator

### **Key Secondary Endpoint**

Overall survival

#### **Other Secondary Endpoints**

Safety


NED, no evidence of disease.

### **Baseline Characteristics**


	Pembrolizumab (N = 496)	Placebo (N = 498)
Age, median (range), yrs	60 (27-81)	60 (25-84)
Male	70.0%	72.1%
ECOG performance status of 0	84.9%	85.5%
Region United States (US) Outside US	23.0% 77.0%	23.5% 76.5%
M stage M0 M1	94.2% 5.8%	94.4% 5.6%
Disease risk category <sup>a</sup> M0 intermediate-high risk M0 high risk M1 NED	85.1% 8.1% 5.8%	86.9% 7.4% 5.6%
Sarcomatoid features Present Absent Unknown	10.5% 83.5% 6.0%	11.8% 83.3% 4.8%
PD-L1 status <sup>b</sup> CPS <1 CPS ≥1 Missing	25.0% 73.6% 1.4%	22.7% 76.9% 0.4%

<sup>a</sup>Another 1.0% of pts in the pembro group and 0% in the placebo group had T2 (grade ≤3) N0 M0 or T1 N0 M0 disease (protocol violations). <sup>b</sup>Assessed with PD-L1 IHC 22C3 pharmDx. PD-L1 combined positive score (CPS) is the # of PD-L1–staining cells (tumor cells, lymphocytes, and macrophages) divided by the total # of viable tumor cells, multiplied by 100. Data cutoff date: September 15, 2023.

### Updated Disease-Free Survival by Investigator, Intention-to-Treat Population







### Overall Survival by Subgroups

	Events/Participants	Hazard Ratio (95% CI)
Overall	141/994	0.62 (0.44-0.87)
<b>Age</b> <65 yrs ≥65 yrs	71/664 70/330	0.51 (0.31-0.83) 0.77 (0.48-1.23)
<b>Sex</b> Female Male	38/288 103/706	1.08 (0.57-2.04) 0.50 (0.33-0.75)
Race White All others	113/748 19/175	
<b>ECOG PS</b> 0 1	105/847 36/147	0.55 (0.37-0.82) 0.84 (0.44-1.63)
<b>PD-L1 status</b> CPS <1 CPS ≥1	28/237 111/748	0.65 (0.31-1.38) 0.62 (0.42-0.91)
Region	27/231	0.68 (0.32-1.47)
Outside United States		——— 0.61 (0.42-0.88)
Mistage M0 M1 NED Bisk estagen	130/937 11/57	0.63 (0.44-0.90) 0.51 (0.15-1.75)
<b>Risk category</b> M0 int/high M0 high M1 NED	110/855 19/77 11/57	0.59 (0.40-0.87) 0.78 (0.32-1.93) 0.51 (0.15-1.75)
Sarcomatoid features Present Absent	20/111 111/829	0.69 (0.28-1.70) 0.57 (0.39-0.84)
Data cutoff date: September 15, 2023.		0.1 0.5 1 1.5 Favors pembro Favors placebo

CITY OF HOPE

### Subsequent Therapies, Intention-to-Treat Population

	Participants with Documented Recurrence		
	Pembrolizumab (N = 161)	Placebo (N = 210)	
Received any subsequent therapy <sup>a,b</sup>	128/161 (79.5%)	171/210 (81.4%)	
Received systemic anticancer drug therapy Anti–PD-(L)1 therapy <sup>c</sup> VEGF/VEGFR inhibitor <sup>a</sup> Other <sup>e</sup>	102/128 (79.7%) 42/102 (41.2%) 94/102 (92.2%) 32/102 (31.4%)	145/171 (84.8%) 101/145 (69.7%) 123/145 (84.8%) 60/145 (41.4%)	
Received radiation therapy	31/128 (24.2%)	33/171 (19.3%)	
Received surgery	35/128 (27.3%)	50/171 (29.2%)	
No subsequent therapy	28/161 (17.4%)	28/210 (13.3%)	
No subsequent therapy data available	5/161 (3.1%)	11/210 (5.2%)	

<sup>a</sup>An additional 4 and 1 pts respectively in the pembro and placebo arms who are not included in the figure received subsequent therapy without documented recurrence. <sup>b</sup>Pts could have multiple subsequent anticancer therapies for RCC; each pt is counted once in each applicable category. <sup>c</sup>Atezolizumab, avelumab, durvalumab, nivolumab, pembrolizumab. <sup>d</sup>Axitinib, bevacizumab, cabozantinib, lenvatinib, pazopanib, sorafenib, sunitinib, tivozanib. <sup>e</sup>Included but was not limited to belzutifan, everolimus, and ipilimumab. Data cutoff date: September 15, 2023.

## RCC Highlights from 2024 – ASCO GU

 Adjuvant pembrolizumab prolonged OS vs placebo in ccRCC at increased risk of recurrence following surgery

o 38% reduction in risk of death vs placebo

- Continued DFS with pembrolizumab was observed with further follow up
- KEYNOTE-564 is the first study to demonstrate a survival benefit with adjuvant therapy in RCC
- Questions remains about subsequent therapy availability, particularly outside the US

## RCC Highlights from 2024 - ASCO

<u>Circulating kidney injury molecule-1 (KIM-1)</u> <u>biomarker analysis in IMmotion010: A randomized</u> <u>phase 3 study of adjuvant atezolizumab vs placebo</u> <u>in patients with renal cell carcinoma at increased</u> <u>risk of recurrence after resection</u>

### Introduction

- In the Phase 3 IMmotion010 trial, adjuvant atezolizumab (anti–PD-L1) did not prolong investigator-assessed DFS vs placebo after resection in patients with RCC with increased risk of recurrence<sup>1</sup>
- Heterogeneity in outcomes across clinical trials evaluating checkpoint inhibitors as adjuvant therapy in RCC<sup>1-4</sup> suggests that there may be patient subpopulations that derive differential benefit from these agents
- Additionally, biomarkers are needed to identify patients with minimal residual disease (MRD) after resection who may have increased risk of recurrence

PD-L1, programmed death-ligand 1. 1. Pal S, et al Lancet 2022;400:359-68. 2. Choueiri T, et al. N Engl J Med 2021;385:683-94. 3. Motzer RJ, et al. Lancet 2023;401:821-32. 4. Choueiri T, et al. N Engl J Med 2024; 390:1359-71.



PRESENTED BY: Laurence Albiges, MD, PhD | IMmotion010 biomarker (#4506)


Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org



## KIM-1 (Kidney injury molecule-1) is a tumor associated protein and may be a useful circulating biomarker in RCC

- KIM-1, a type 1 membrane glycoprotein, has been identified as a marker of unresected clear-cell RCC and as a marker for early detection of RCC<sup>1,2,3</sup>
- In the ASSURE trial of adjuvant sunitinib, sorafenib, or placebo, higher levels of KIM-1 in postnephrectomy, pre-treatment plasma samples were associated with worse DFS and OS<sup>4</sup>
- KIM-1 can be measured in plasma or serum and is stable under different storage conditions, suggesting suitability to serve as a peripheral blood circulating biomarker<sup>5</sup>

### KIM-1 IHC analysis in RCC Primary Tumor



Kushlinskii NE, et al. Bull Exp Biol Med 2019; 167:388-92.
Scelo G, et al. Clin Cancer Res 2018;24:5594-601.
Xu W, et al. J Clin Oncol 2024; JCO2300699.
Xu W, et al. Clin Cancer Res 2021;27:3397-403.
Hou W, et al. Transpl Rev 2010; 24:143-6.




PRESENTED BY: Laurence Albiges, MD, PhD | IMmotion010 biomarker (#4506)

Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org.




## KIM-1 was identified as the most significantly enriched circulating protein in recurrence vs baseline serum samples in IMmotion010



9

## Baseline KIM-1 level of 86 pg/mL was identified as the optimized threshold for defining KIM-1<sup>High</sup> vs KIM1<sup>Low</sup> subgroups





12

#ASCO24 PRESENTED BY: Laurence Albiges, MD, PhD | IMmotion010 biomarker (#4506)

Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org.

2024 ASCO

ANNUAL MEETING

### **Baseline characteristics by KIM-1 status**

Baseline

Characteristic	KIM-1 <sup>High</sup>	KIM-1 <sup>∟ow</sup>
	(n=300)	(n=452)
Age, median (range), y	64 (56-70)	58 (50-67)
Male, n (%)	232 (77)	314 (69)
Region, n (%)ª		
Europe and Middle East	128 (43)	207 (46)
North America	102 (34)	172 (38)
Asia-Pacific	53 (18)	23 (5)
Central or South America	12 (4)	41 (9)
Australia	5 (2)	9 (2)
Pathologic disease stage, n (%)		
T2/T3a	171 (57)	313 (69)
T3b/c/T4/N+	81 (27)	82 (18)
M1 NED	48 (16)	57 (13)
Disease stage, n (%)		
	16 (5)	14 (3)
11	21 (7)	26 (6)
111	249 (83)	388 (86)
IV	14 (5)	24 (5)
PD-L1 Status <sup>a</sup>	•••	
PD-L1 positive	188 (63)	266 (59)
PD-L1 negative	112 (37)	186 (41)
Sarcomatoid component	48 (16)	51 (11)

PD-L1 evaluated using SP142 assay, PD-L1 positive was defined as ≥1% tumor infiltrating immune cells expressing PD-L1.



PRESENTED BY: Laurence Albiges, MD, PhD | IMmotion010 biomarker (#4506)


Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org.



13

### KIM-1<sup>High</sup> status at baseline was associated with worse DFS in IMmotion010

**Baseline** 



	n Median DFS (months)		HRª (95% CI)
KIM-1 <sup>High</sup>	300	35.88	4 75 (1 40 0 47)
KIM-1 <sup>Low</sup>	452	57.23	1.75 (1.40, 2.17)



PRESENTED BY: Laurence Albiges, MD, PhD | IMmotion010 biomarker (#4506)

AMERICAN SOCIETY OF CLINICAL ONCOLOGY KNOWLEDGE CONQUERS CANCER

Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org.

## Atezolizumab improved DFS vs Placebo in the baseline KIM-1<sup>High</sup> subgroup

**Baseline** KIM-1<sup>High</sup> subgroup KIM-1<sup>Low</sup> subgroup --- Placebo Placebo 0.9 0.9 --- Atezolizumab Atezolizumab 0.8 0.8 0.7 0.7. % DFS % 0.6 0.6-DFS 0.5 0.5 0.4 0.4 0.3 0.3-0.2-0.2-0.1 0.1. 21.16 57.23 0 0 \_\_\_\_\_ 0 4 8 12 16 20 24 28 32 36 40 44 48 52 56 0 4 8 12 16 20 24 28 32 36 40 44 48 52 56 60 Time (months) Time (months) **Median DFS** HR<sup>a</sup> (95% CI) Median DFS HR<sup>a</sup> (95% CI) n n Atezolizumab 57.23 Atezolizumab 151 NE 229 1.12 (0.88, 1.63) 0.72 (0.52, 0.99) 21.16 NE Placebo 149 223 Placebo

<sup>a</sup> HR stratified by pathologic disease stage and geographic region.



PRESENTED BY: Laurence Albiges, MD, PhD | IMmotion010 biomarker (#4506)


Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org



16

### In the KIM-1<sup>High</sup> subgroup, patients were less likely to experience an on-treatment increase in KIM-1 levels with atezolizumab vs placebo treatment

**On Treatment** 



<sup>a</sup> Increase in KIM-1 was defined as a ≥30% increase from baseline to Cycle 4 Day 1 value.

2024 ASCO #A


#ASCO24 PRESE

PRESENTED BY: Laurence Albiges, MD, PhD | IMmotion010 biomarker (#4506) Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org.



18

## On-treatment increase in KIM-1 was associated with worse DFS in both KIM-1<sup>High</sup> and KIM-1<sup>Low</sup> subgroups



### Time (months)


Baseline	On-treatment	n	Median DFS	HR (95% CI)
KIM-1 <sup>High</sup>	Increasea	12	14.8	1 69 (0 77 3 60)
VIIVI-1	No increase	126	NE	1.68 (0.77, 3.69)
	Increasea	34	11.5	2.50 (2.24 .5.75)
KIM-1 <sup>Low</sup>	No increase	179	NE	3.56 (2.21, 5.75)

<sup>a</sup>Increase in KIM-1 was defined as a ≥30% increase from baseline to Cycle 4 Day 1 value.



PRESENTED BY: Laurence Albiges, MD, PhD | IMmotion010 biomarker (#4506)


Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org.



### Time (months)

Baseline	On-treatment	n	Median DFS	HR (95% CI)	
KIM-1 <sup>High</sup>	Increasea	36	4.8	3.53 (2.24, 5.58)	
KIM-1 <sup>mgn</sup>	No increase	105	45.4		
	Increasea	28	29.0	2 54 (4 42 4 44	
KIM-1 <sup>Low</sup>	No increase	179	NE	2.51 (1.42, 4.44)	





### Serum KIM-1 levels increased at time of disease recurrence vs baseline

a Analysis conducted in patients with matched samples at baseline and at disease recurrence or at treatment discontinuation without disease recurrence (approximately 1 year or 16 treatment cycles)

2024 ASCO ANNUAL MEETING #ASCO24 PRESENTED BY: Lau Presentation is property of

**Disease Recurrence**/

PRESENTED BY: Laurence Albiges, MD, PhD | IMmotion010 biomarker (#4506)

Presentation is property of the author and ASCO. Permission required for reuse; contact permissions@asco.org.



20

## RCC Highlights from 2024 - ASCO

 In IMmotion010, elevated post-nephrectomy KIM-1 serum levels showed potential as a circulating protein biomarkers for minimal residual disease and disease recurrence in the adjuvant setting

 $\odot$  High post-nephrectomy KIM-1 serum levels were associated with worse DFS  $\odot$  An increase in post-treatment KIM-1 levels was associated with worse DFS

- Atezolizumab showed improved DFS vs placebo in patients with high baseline KIM-1
- Standardized cutoffs are needed before KIM-1 can be used in clinical decision making

## RCC Highlights from 2024 - ESMO

<u>Tivozanib Plus Nivolumab vs Tivozanib Monotherapy</u> <u>in Patients with Metastatic Renal Cell Carcinoma</u> <u>Following an Immune Checkpoint Inhibitor: Results</u> <u>of the Phase III TiNivo-2 Study</u>

### Background

- The optimal sequence in patients whose disease progressed after treatment with ICI is uncertain, leaving several unanswered questions:
  - Can ICI rechallenge improve clinical outcomes?
  - Can outcomes be impacted if non-ICI drugs were used before ICI rechallenge (ICI break)?
  - Any differences between anti–PD-1 or anti–PD-L1 therapies in the rechallenge setting?
- Evidence supports the value of VEGFR TKI use, including tivozanib, in patients previously treated with ICI-based regimens<sup>1,2</sup>
- Tivozanib was evaluated in combination with nivolumab in the phase 1/2 TiNivo study showing promising antitumor efficacy with an expected adverse event profile in patients with mRCC<sup>3</sup>




ICI, immune checkpoint inhibitor; PD-1, programmed cell death protein 1; PD-L1, programmed cell death ligand 1; mRCC, metastatic renal cell carcinoma; VEGFR-TKI, vascular endothelial growth factor receptor tyrosine kinase inhibitor. 1. Pal SK, et al. *Lancet.* 2023;402:185-195. 2. Rini BI, et al. *Lancet Oncol.* 2020;21:95-104. 3. Albiges L, et al. *Ann Oncol.* 2021;32:97-102.

### **TiNivo-2: Phase 3 Study Design**

Locally advanced or metastatic clearcell RCC after progression on 1 or 2 lines of therapy, one of which was an ICI:

- Progression during or following ≥6 weeks of treatment with ICI
- Progression no longer than 6 months prior to randomization.
- Measurable disease (RECIST v1.1)
- ECOG PS: 0 or 1



### **Stratification Factors**

- IMDC risk category
- Prior therapy (ICI as most recent therapy or not)

### **Key Considerations**

- Reduced dose of tivozanib in combination arm was agreed with regulatory authorities due to potential risk of higher rate of grade 3/4 hypertension
- Prior therapy (ICI as most recent therapy or not)
  - Test if ICI break impacts outcome (reset the immune system?)

\*Treatment was continued until progression or unacceptable toxicity, nivolumab discontinued in all subjects after 2 years of treatment.



DOR, duration of response; ECOG PS, Eastern Cooperative Oncology Group performance status; ICI, immune checkpoint inhibitor; IMDC, International mRCC Database Consortium; INV, investigator; IRR, independent radiology review; IV, intravenous; ORR, objective response rate; OS, overall survival; PO, by mouth; PFS, progression-free survival; RCC, renal cell carcinoma; RECIST, Response Evaluation Criteria in Solid Tumors

1. ClinicalTrials.gov. Accessed May 20, 2024. https://clinicaltrials.gov/study/NCT04987203.

### **Baseline Demographics and Disease Characteristics**


Characteristic	Tivozanib + Nivolumab (N=171)	Tivozanib (N=172)
<b>Age, years</b> Median (range)	63 (37-87)	62 (33-82)
<b>Sex, n (%)</b> Female Male	46 (27) 125 (73)	38 (22) 134 (78)
Race, n (%) White Asian Black or African American Not reported	112 (65) 1 (<1) 2 (1) 56 (33)	107 (62) 0 8 (5) 57 (33)
ECOG PS, n (%) 0 1 Missing	76 (44) 94 (55) 1 (<1)	85 (49) 87 (51) 0

Characteristic	Tivozanib + Nivolumab (N=171)	Tivozanib (N=172)
IMDC Risk Category, n (%) Favorable Intermediate Poor	30 (18) 114 (67) 27 (16)	31 (18) 113 (66) 28 (16)
Prior Lines of Therapy, n (%) 1 2	111 (65) 60 (35)	105 (61) 67 (39)
Most recent therapy, n (%) ICI Non-ICI	119 (71) 49 (29)	122 (71) 50 (29)
<b>Prior VEGF-TKI Use, n (%)</b> 0 1 2	51 (30) 95 (57) 22 (13)	53 (31) 100 (58) 18 (11)



4

### Primary Analysis of Centrally Reviewed PFS (primary endpoint)




Median follow up was 11.8 months for the tivozanib + nivolumab cohort and 12.5 months for tivozanib monotherapy

HR, hazard ratio; IRR, independent radiology review; ITT, intent to treat.

BARCELON/ 2024

### **Centrally Reviewed PFS by Line of Therapy**




### Second Line Therapy

### **Third Line Therapy**



### **Centrally Reviewed PFS by Most Recent Line of Therapy**



### **ICI as Most Recent Therapy**


### Non-ICI as Most Recent Therapy



### Centrally reviewed PFS by subgroup

	Tivoza	nib + Nivolumab		Tivozanib		
Category	Event/N	Median PFS, Months (95% CI)	Event/N	Median PFS, Months (95% CI)		PFS HR (95% Cl)
Age						
< 65 years	68/89	4.8 (3.4–7.3)	65/97	7.4 (5.5–9.2)	⊢┼╼───┤	1.25 (0.89–1.76)
≥ 65 years	50/82	9.2 (5.5–9.6)	47/75	7.6 (5.2–10.0)		0.92 (0.61–1.37)
Gender Male	86/125	5.6 (3.9–7.5)	88/134	7.4 (5.5–9.2)		1.01 (0.75–1.36)
Female	32/46	6.7 (3.7–10.9)	24/38	7.4 (5.6–12.9)		1.27 (0.75–2.16)
ECOG	02/10	0.1 (0.1-10.0)	24/00	1.4 (0.0–12.0)		1.27 (0.70-2.10)
0	52/76	7.3 (4.0–9.4)	53/85	8.8 (7.2–11.1)		1.15 (0.78–1.69)
1	66/94	5.5 (3.7–9.0)	59/87	6.0 (3.7–8.6)		0.95 (0.67–1.36)
IMDC Risk Category						
Favorable	18/30	9.3 (4.0–11.4)	15/31	11.2 (9.3–13.1)		1.37 (0.69–2.73)
Intermediate	78/114	5.7 (4.0-9.4)	75/115	7.4 (4.5-8.4)		0.99 (0.72-1.36)
Poor	22/27	3.7 (2.7–7.4)	22/26	5.7 (2.3–9.2)	⊢ <b>⊢</b> ∎−−−−−−1	1.35 (0.73-2.50)
Use of VEGFR-TKI in recent line						
Yes	37/45	3.4 (2.2-4.8)	37/50	3.7 (1.9–7.2)	⊢ <b>_</b> →	0.96 (0.61–1.52)
No	37/66	9.6 (7.5–11.2)	36/65	9.3 (7.4–14.7)		0.95 (0.60–1.51)
Previous use of VEGFR-TKI (any	prior line)					
0 VEGFR-TKI	29/53	9.6 (7.4–15.3)	28/53	9.4 (7.4–15.5)	⊢ <b>⊢</b>	1.03 (0.61–1.74)
1 VEGFR-TKI	69/96	5.4 (3.7–6.7)	70/101	7.4 (5.5–8.8)	⊢ <b>⊢</b>	1.04 (0.74–1.45)
2 VEGFR-TKI	20/22	3.1 (2.1–4.0)	14/18	3.8 (1.9–7.2)	⊢ <b>_</b>	1.33 (0.67–2.65)
			🔶 Tive	ozanib + Nivolumab	better Tivozanib better	<b>→</b>
ONA FS Congress				0	1 2	3





### **Safety Summary**

Adverse Event, n (%)	Tivozanib 0.89 mg + Nivolumab (n=168)	Tivozanib 1.34 mg (n=171)
Any-cause TEAE, n (%)	<b>163 (97)</b>	<b>167 (98)</b>
Related TEAE	137 (82)	144 (84)
Tivozanib	135 (80)	144 (84)
Nivolumab	119 (71)	0
Grade 3 or 4 AE, n (%)	<b>102 (61)</b>	<b>103 (60)</b>
Related	54 (32)	60 (35)
Serious AE, n (%)	<b>54 (32)</b>	<b>64 (37)</b>
Related	14 (8)	15 (9)
Death due to AE, n (%)	<b>7 (4)</b>	<b>5 (3)</b>
Related	0	1 (<1)
<b>TEAE leading to discontinuation, n (%)</b>	<b>27 (16)</b>	<b>33 (19)</b>
Due to tivozanib	19 (11)	33 (19)
Due to nivolumab	22 (13)	0
<b>TEAE leading to dose interruption, n (%)</b>	<b>82 (49)</b>	<b>93 (54)</b>
Due to tivozanib	79 (47)	93 (54)
Due to nivolumab	35 (21)	0
TEAE leading to dose reduction of tivozanib, n (%)	18 (11)	38 (22)
Median duration of treatment, months (range)	6.3 (0.0, 20.7)	7.4 (0.1, 17.9)



CITY OF HOPE

## RCC Highlights from 2024 - ESMO

- The addition of nivolumab to tivozanib did not result in improved clinical outcomes in patients with mRCC who progressed on or after prior ICI treatment
- Tivozanib with or without nivolumab was tolerated and consistent with the established safety profiles of these agents
- Meaningful results were observed in the tivozanib monotherapy arm with a 9.2 months mPFS immediately following ICI and as a second line treatment following ICI combinations.
- This trial confirms the key conclusion from CONTACT-03 ICI re-challenge in mRCC should be discouraged regardless of treatment sequence

# Thank you!